PURASORB PLG 1017 is an acid-terminated poly(L-lactide-co-glycolide) 10:90 copolymer with a midpoint inherent viscosity of approximately 0.17 dL/g measured in chloroform at 25°C. The 10:90 L-lactide:glycolide molar ratio places the material in the fast-degrading segment of the PLGA family, with bulk erosion dominated by ester bond hydrolysis and autocatalytic acceleration from acidic degradation products. The acid-terminated architecture reduces molecular weight distribution tailing and improves solubility in dichloromethane, chloroform, tetrahydrofuran, N-methyl-2-pyrrolidone, dimethyl sulfoxide, acetonitrile, 1,4-dioxane, and ethyl acetate, while water and primary alcohols are nonsolvents. The low inherent viscosity reduces solution viscosity at high polymer loading but limits melt strength, making the grade unsuitable for load-bearing extruded implants unless blended with higher-lactide or higher-molecular-weight PLGA grades. The following application tracks cover six medical device downstream segments in which PLG 1017 is used as a principal matrix, a dissolution-rate modifier, or a carrier polymer.

Long-acting injectable microsphere systems represent the highest-volume downstream application for low inherent viscosity acid-terminated 10:90 PLGA grades. In a water-in-oil-in-water double-emulsion process, PLG 1017 is dissolved in dichloromethane at 5–18% w/v, while the active pharmaceutical ingredient is either co-dissolved in the organic phase or introduced as an aqueous internal phase at a drug-to-polymer mass ratio from 1:4 to 1:20 depending on peptide or small-molecule solubility. The primary emulsion is generated under rotor-stator high-shear mixing at 3,000–10,000 rpm with a Silverson L4RT or IKA T25 digital ULTRA-TURRAX fitted with a fine-rotor workhead; the secondary emulsion is transferred into 0.5–2% w/v aqueous polyvinyl alcohol at 10–25°C. Solvent extraction and evaporation are performed in jacketed reactors with a controlled ramp from 15°C to 40°C over 4–8 h. Terminal microspheres are collected by sieving, washed with water for injection, and lyophilized at primary drying shelf temperatures of −35°C to −20°C and secondary drying at +15°C to +25°C. Process failure modes observed on production lines include batch-to-batch variability in primary emulsion viscosity when the aqueous drug phase exceeds 20% of the organic phase volume, leading to bimodal particle size distributions, and in-line laser diffraction analysis with a Malvern Mastersizer 3000 is used to control mean particle size and span. Compliance boundaries include Ph. Eur. 2.6.12 and 2.6.13 for microbial examination, USP <788> for particulate matter, USP <85> for bacterial endotoxins, ICH Q3C(R8) for residual dichloromethane and polyvinyl alcohol, ISO 10993-6 for local intramuscular implantation effects, and ISO 13485:2016 process controls. Finished product types include sterile microsphere vials for reconstitution, dual-chamber prefilled syringes with diluent compartments, and single-dose reconstitution kits for peptide-loaded depot injections where release typically spans 1–3 months depending on drug-polymer distribution and particle size.

What Limits Drug-Eluting Stent Coating Uniformity on Cobalt-Chromium Struts?

PLG 1017 is dissolved at 1–4% w/v in chloroform/tetrahydrofuran 90:10 v/v or acetone/ethyl acetate blends for drug-eluting stent coating. Antiproliferative active pharmaceutical ingredient is added at a drug-to-polymer mass ratio of 1:2 to 1:3, yielding a target drug content of 0.8–1.5 µg/mm² on 60–120 µm struts. Ultrasonic spray coating at 20–60 kHz with a Sono-Tek MediCoat or equivalent atomizer is performed while the stent rotates at 100–200 rpm and translates at 0.5–2 mm/s under laminar flow at 40–60°C. Critical defects observed at scale include webbing at sidewall radii, orange-peel topography, and polymer bridging across strut gaps; these are controlled by adjusting atomizer power, solution viscosity, and drying airflow. The low acid-terminated 10:90 grade has a relatively low glass transition temperature, typically near 35–45°C, so coatings may exhibit blocking if spooled at ambient temperatures above 30°C without secondary drying. Compliance standards include ISO 25539-2:2020 for cardiovascular stent systems, ISO 10993-4 hemocompatibility, ISO 10993-5 genotoxicity, ISO 10993-6 implantation, ISO 10993-11 systemic toxicity, USP <788> particulate matter, and ISO 10993-18 chemical characterization for residual tin catalyst or processing additives. Terminal finished products include coronary drug-eluting stent systems, peripheral below-the-knee stent systems, and coated stent subassemblies supplied to original equipment manufacturers. Published comparative release data for PLG 1017 in fully approved drug-eluting stent formulations is limited; development batches are routinely characterized by USP Apparatus 7 reciprocating holder dissolution and scanning electron microscopy for coating integrity.

In-situ forming injectable depots prepared from PLG 1017 and N-methyl-2-pyrrolidone or dimethyl sulfoxide exploit the copolymer’s solubility in water-miscible aprotic solvents and its acid-terminated hydrophilic architecture. PLG 1017 is dissolved at 30–45% w/v in NMP with the active pharmaceutical ingredient co-dissolved or suspended at a final drug load of 3–15% w/w; the solution is filtered through 0.22 µm PVDF membranes and filled into single-use syringes under a dry nitrogen atmosphere with residual moisture kept below 0.1% w/w. Upon injection into aqueous physiological fluid or subcutaneous tissue, solvent exchange with water precipitates the PLGA matrix as a depot. Depot morphology is controlled by polymer concentration, solvent selection, injection volume, and tissue vascularity. Production equipment includes bubble-free vacuum mixing, nitrogen-blanketed filling lines, and terminal sterilization by gamma irradiation at 25–40 kGy where drug stability permits. Compliance includes ISO 10993-6 for local tissue response, ISO 10993-11 for systemic toxicity, USP <787> subvisible particulate matter for therapeutic protein injections, USP <790> visible particulates, and ICH Q3C(R8) residual solvent limits for NMP and DMSO. Terminal finished products include prefilled syringes with luer-lock adapters, cartridge-based depot injector systems, and kit configurations with separate diluent and polymer-solution cartridges. The main operational boundary is that hydrated PLG 1017 degrades rapidly; precompounded solution must be stored at −20°C to 5°C, and hold times above 24 h at 25°C increase bulk viscosity drift and acid shift.

Transdermal Bioresorbable Microneedle Arrays Formed by Vacuum-Assisted Mold Filling

PLG 1017 is used as a bioresorbable matrix in microneedle arrays because its low inherent viscosity permits filling of high-aspect-ratio polydimethylsiloxane molds without excessive bubble entrapment. The copolymer is dissolved at 10–25% w/v in acetonitrile, 1,4-dioxane, or dimethyl sulfoxide, with vaccine antigens, lidocaine hydrochloride, or cosmetic actives added at 1–20% w/w of total solids. The solution is cast onto PDMS molds with 500–850 µm pyramidal or conical cavities, subjected to vacuum-assisted filling at 0.2–0.5 bar for 5–15 min, and dried at 25–40°C for 12–24 h before demolding. Needle fracture during demolding is the primary failure mode because the 10:90 copolymer has low molecular weight and limited tensile strength; blending with 5–10 wt% poly(ethylene glycol) 400 or PLGA 50:50 improves flexibility but accelerates release. Compliance includes ISO 10993-5 for cytotoxicity, ISO 10993-10 for skin irritation and sensitization, ISO 10993-18 for leachables, and ISO 13485:2016 for manufacturing controls; terminal patch assembly is conducted in ISO 14644-1 Class 7 cleanrooms. Finished product types include dissolvable vaccine patches, transdermal lidocaine microneedle arrays, and cosmetic hyaluronic acid delivery patches with 100–400 needles per cm².

Solvent-cast bioresorbable adhesion barrier films using PLG 1017 are produced by dissolving the copolymer at 8–15% w/v in chloroform or ethyl acetate, casting onto release liners, and drying in controlled laminar-air ovens at 30–50°C. Films with thicknesses of 20–80 µm are cut to 5×5 cm or 10×10 cm sheets and sterilized by ethylene oxide at 45–55°C. The acid-terminated 10:90 L:G composition yields a degradation window of approximately 4–8 weeks in mesothelial tissue, which is frequently too short for full peritoneal healing; therefore blend formulations with 20–40 wt% PLGA 50:50 or 75:25 grades are typical. Addition ratios for PLG 1017 in these blends range from 10–35 wt% of total polymer solids, balancing flexibility and hydrolysis rate. Residual ethylene oxide, ethylene glycol, and ethylene chlorohydrin are controlled per ISO 10993-7:2008/Amd1:2019 with maximum daily dose allowances specific to patient contact duration. Compliance includes ISO 10993-5 for cytotoxicity, ISO 10993-6 for local implantation, ISO 10993-10 for skin sensitization, and ASTM F2902-16 for absorbable polymeric implant assessment. Terminal finished products include absorbable anti-adhesion sheets, pericardial patches, and pelvic surgery barrier films. Films with PLG 1017 content above 30 wt% may exhibit brittle handling when dried below glass transition; thermal annealing at 35–45°C for 2–4 h reduces curl and static charge during die cutting.

When Low Molar Mass PLGA 10:90 Modifies Guided Tissue Regeneration Membranes

In dental guided tissue regeneration, PLG 1017 functions as a low-molecular-weight absorbable modifier in solvent-cast or electrospun barrier membranes where faster hydrolysis of the 10:90 fraction creates microporosity and promotes cell infiltration after the initial barrier period. PLG 1017 addition at 5–20% w/w of total polymer solids is blended with PLGA 75:25 or poly(ε-caprolactone) before electrospinning from 8–12% w/v solutions in hexafluoroisopropanol or chloroform/ethanol 80:20 v/v. Electrospinning is performed at 12–20 kV, a flow rate of 0.5–2.0 mL/h through 22G needles, and a collector distance of 10–18 cm, producing nanofibrous membranes with fiber diameters of 300–900 nm. A critical process conflict is that PLG 1017 reduces solution viscosity and may cause droplet formation or beading when added above 20 wt%; electrospinning trials therefore require repeated adjustment of flow rate and voltage. Compliance includes ISO 22803:2004 for dental barrier membranes, ISO 10993-1:2018 biological evaluation, ISO 10993-5 for cytotoxicity, ISO 10993-6 for implantation, and ISO 10993-18 for chemical characterization. Terminal finished products include resorbable dental guided tissue regeneration membranes, socket preservation barriers, and periodontal defect repair sheets supplied in sterile double-peel pouches.